References
- Erlinge D, Edvinsson L, Ekmamm R, Thulin T. Neuropeptide Y-like immunoreactivity and hypertension. J Hypertens 1992; 10: 1221–5
- Edvinsson L, Ekman R, Thulin T. Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul Pept 1991; 32: 279–87
- Folkow B. Sympathetic nervous control of blood pressure. Role in primary hypertension. Am J Hypertens 1989; 2: 103–11
- Lundberg J, Hökfelt T. Multiple co-existence of peptides and classical transmitters in peripheral autonomic neurons—functional and pharmacological implications. Prog Brain Res 1986; 68: 241–62
- Edvinsson L, Hakanson R, Wahlestedt C, Uddman R. Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol Sci 1987; 8: 231–5
- Edvinsson L, Adamsson M, Jansen I. Neuropeptide Y antagonistic properties of D-myo-inositol-1, 2, 6-trisphosphate in guinea pig basilar arteries. Neuropeptides 1990; 17: 99–105
- Sun X, Edvinsson L, Hedner T. Neuropeptide Y-induced pressor responses in spontaneously hypertensive and Wistar-Kyoto rats antagonized by D-myo-inositol-1, 2, 6-trisphosphate (α-Trinositol). J Pharmacol Exp Ther 1991; 9(Suppl 6)344–5
- Sun X, Edvinsson L, Hedner T. Effects of D-myo-inositol-1, 2, 6-trisphosphate on neuropeptide Y-induced potentiation of various vasoconstrictor agents in the rat. J Hypertens 1992; 261: 1147–52
- Adamsson M, Fallgren B, Edvinsson L. Inhibition of neuropeptide Y-induced potentiation of noradrenalin-induced vasoconstriction by PP56 (D-myo-inositol-1, 2, 6-trisphosphate). Br J Pharmacol 1992; 105: 93–6
- Lind H, Nilsson P, Holthuis N, Lindholm L. Non-obese men with high lipoprotein(a)-values—a cardiovascular risk group different from those with the metabolic syndrome?. Scand J Clin Lab Invest 1994, (in press)
- Guidelines sub-committee of the WHO/ISH mild hypertension liaison committee. 1989 guidelines for management of mild hypertension: memorandum from a WHO/ ISH meeting. J Hypertens 1989; 7: 689–93
- Wallin L, Brudin H. Physical working capacity determined by different types of bicycle exercise tests. Clin Physiol 1988; 8: 529–37
- Nordenfeldt I, Adolfsson L, Nilsson J, Olsson S. Reference values for exercise tests with continuous increase in load. Clin Physiol 1985; 5: 161–72
- Solt V, Brown M, Kennedy B, Kolterman O, Ziegler M. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 1990; 3: 823–8
- Ullman B, Franco-Cereceda A, Hulting J, Lundberg J, Sollevi A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischemia in man. J Intern Med 1990; 228: 583–9
- Kaijser L, Pernow J, Berglund B, Lundberg J. Neuropeptide Y is released with noradrenalin from the human heart during exercise and hypoxia. Clin Physiol 1990; 10: 179–88
- Morris M J, Russel A E, Kapoor V, et al. Increase in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 1986; 17: 143–7
- Potter E, Edvinsson L, Gustafsson T. Antagonism of pre-and postjunctional responses to neuropeptide Y and sympathetic stimulation by D-myo-inositol-1, 2, 6-trisphosphate in the anaesthetized dog. Eur J Pharmacol 1992; 221: 307–14
- Schwieler J, Hjelmdahl P. D-myo-inositol-l, 2, 6-trisphosphate (PP56) antagonizes non-adrenergic sympathetic vasoconstriction: possible involvement of neuropeptide Y. J Cardiovasc Pharmacol 1993; 21: 347–52
- Edvinsson L, Erlinge D, Sun X, Hedner T. Neuropeptide Y in sympathetic co-transmission—Recent advances in the search for neuropeptide Y antagonists. Pharmacol Toxicol 1994, (in press)